Blood-based test can predict risk of developing symptoms of Alzheimer's up to a decade early. A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged about the extent to which such tests can accurately predict whether a cognitively healthy individual will develop cognitive impairment—a key symptom of Alzheimer's disease.
A apuração publicada por medicalxpress.com vira base para uma leitura editorial direta e contextualizada.
Trechos de apoio da pauta: A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged about the extent to which such tests can accurately predict whether a cognitively healthy individual will develop cognitive impairment—a key symptom of Alzheimer's disease.
- Ponto de atenção: blood.
- Ponto de atenção: based.
- Ponto de atenção: test.
Em resumo, a leitura editorial acompanha o impacto do tema no nicho Fitness.
